中国自主研发的老年痴呆症药物完成了第三期临床试验

China’s domestically-made new drug to treat Alzheimer’s disease completed its phase 3 clinical trial on Tuesday, a breakthrough that marks the most critical step in the drug development and the last test before entering the market.

中国国内生产的治疗阿尔茨海默病的新药周二完成了第三期临床试验，这一突破标志着药物研发的关键一步，也是进入市场之前的最后一次试验。

The new drug, named “GV-971”, was co-developed by Ocean University of China, Shanghai Institute of Materia Medica under Chinese Academy of Sciences and Green Valley Pharmaceutical Co., Ltd, after 21 years’ efforts.

这种新药名为“GV-971”，经过21年的努力，由中国海洋大学、中国科学院上海药物研究所和绿色谷制药有限公司共同开发。

It was extracted from brown algae and targeted at patients with mild-to-moderate Alzheimer’s. The phase 3 clinical trial was to testify the effectiveness and security of the new drug to such patients.

它是从褐藻中提取出来的，针对的是轻度到中度老年痴呆症的患者。第三阶段临床试验是为了向这些患者证明新药的有效性和安全性。

After the 36-week trial, during which patients took 450 mg of this drug orally twice a day, the drug was proved to meet the expectation in improving patients’ cognitive function. Some became literate and were able to write from illiteracy, showing an obvious effect, according to the doctor in charge of the clinical trial.

在为期36周的试验中，患者每天两次口服该药物450毫克，实验证明该药物在改善患者认知功能方面达到了预期。据负责临床试验的医生说，有些人识字了，还能写字，显示出明显的效果。

In the latest research, GV-971 also showed its effectiveness in restraining Alzheimer’s progression by regulating the immune system and reducing neuro-inflammation.

在最新的研究中，GV-971还显示了它通过调节免疫系统和减少神经炎症来抑制阿尔茨海默病的进展。

Alzheimer’s disease is an irreversible, progressive brain disorder that slowly destroys memory, thinking skills, and the ability to carry out simple tasks. Roughly 48 million people globally have been affected by it so far.

阿尔茨海默氏症是一种不可逆的、渐进性的大脑疾病，它会慢慢地破坏记忆、思维能力和完成简单任务的能力。到目前为止，全球约有4800万人受到影响。

The successful trial paves the way for the research of new drugs to treat Alzheimer’s, playing a significant role in enhancing China’s international status in the field of drug research innovation.

成功的试验为老年痴呆症新药的研究铺平了道路，对提高我国在药物研究创新领域的国际地位具有重要作用。